Meet our leaders who guide our purpose to deliver life-changing therapies to patients.
Xiaoping Ye, PhD
EMBA of Guanghua School of Management, Peking University, Obtained PhD in Oxford University UK.
Dr. Ye has over 10 years of experience in medical and regulatory affairs with global pharmaceutical industries. He is the former medical director at Shanghai Roche for 6 years.
Nearly 25-year working experience in drug research and development, regulatory affairs, and clinical research, with 15 years of experience in business management.
Mr. Hao Wu joined Tigermed as Senior Vice President in January 2020, and was appointed as Co-President in August 2021. He has over 17 years of experience in the pharmaceutical industry as the APAC Business Director, Marketing Director, and Portfolio Manager in Schering-Plough, Roche China, Eisai, SciClone Pharmaceuticals, etc. He also has over 10 years of management experience as General Manager at Meixin Insurance.
Zhuan (Helen) Yin
Has 24+ years of experience in management and statistical analyses in the pharmaceutical industry worldwide, including 14 years in United States and 10 years in China/Asia Region.
Founded MacroStat in November 2005 and has become the head of Biometrics for Tigermed Group since 2009. Prior to that, Helen worked 10 years in AstraZeneca US and was Associate Director and US Biostatistical therapeutic leader for breast cancer.
BA in Law from Fudan University (1984-1988), MS in Biostatistics from University of Massachusetts, Amherst (1991-1993).
Zengyu (Michael) Wen
Responsible for the daily operation and management of MacroStat (China) Clinical Research Co., Ltd., Jiaxing Tigermed Data Management Co., Ltd. and Tigermed Xinze Medical Technology (Jiaxing) Co., Ltd.
M.S. in Epidemiology and Biostatistics from Fudan University, MBA from Webster University
Over 15 years of experience in management and biostatistics in the pharmaceutical industry, including 6 years in Schering-Plough
Ruibo Chen, MD
Ruibo Chen graduated from Medical sub-institute, Shanghai Jiao Tong University on July 2000 on hematology, has over 30 years of experience across clinical project management, team management. She joined Tigermed on May 2011, and has served consecutively as Medical Director, Senior Medical Director, Vice President and other important management positions in Clinical Operation Division of Tigermed.
Jiansong Yang, PhD
Joined Tigermed on February 2020, PhD in University of Sheffield on Pharmacokinetic. Founder and General Manager of Mosim since 2015, deep expertise in innovative drug, clinical development strategy, clinical trial design.
Xia Chen, PhD
Dr. Xia Chen holds a Doctor of Medicine in Clinical Medicine from Peking Union Medical College and a Doctor degree in Clinical Pharmacology from Leiden University in the Netherlands. She also holds a Master’s degree in Quantitative Pharmacology from the University of Manchester United Kingdom. Prior to joining Tigermed, she has held critical positions including Associate Professor at Clinical Pharmacology Research Center of Peking Union Medical College, Professor of Clinical Pharmacology at Beijing Tiantan Hospital, and Clinical Reviewer at Center for Drug Evaluation (CDE) of NMPA, with 15 years of clinical R&D experience in hospitals and rich academic research experience.
Over 20-year clinical trial experiences, including 9 years in Shanghai Roche to involve project management and monitor activities; meanwhile to responsible for an international multi-center trial as China Local Project Leader. 3-year working experiences as QA manager working with global QA focusing on trial audit in China.
Over 10-year experiences at Tigermed of quality assurance on clinical trial related activities including QMS, auditing as well as GCP training.
Fully responsible for medical device related services under Tigermed. Engaged in management in biopharmaceutical R&D and production, pharmaceutical product investment management, medical device registration, pharmaceutical and medical device clinical trial field in Chinese and foreign companies, with a deep understanding of Chinese pharmaceutical product transformation, medical device clinical trial management and registration. Master of Biochemistry from East China Normal University, licensed pharmacist, special expert of China Medical Device Industry Association Clinical Trial Branch. Nearly 20 years of practical experience in the pharmaceutical field.
Tianrong Ji, MD
Tianrong Ji, M.D, graduated from Peking Union Medical College, Chinese Academy of Medical Sciences in 1994 and has worked at Peking Union Medical College Hospital, Xi’an Janssen, Roche, Baxter, Fresenius-Kabi etc. She joined Tigermed in July 2014, served as the General Manager of TigerYeah Investment, Vice President and Head of Tigermed Investment Bussiness Unit and has more than twenty years of experience in clinical medicine, fund management and corporate M&A.
Ms. Chengcheng Yang (Grace), MBA, Zhejiang University. Before joining Tigermed, Ms. Chengcheng Yang worked in PricewaterhouseCoopers, Xizi Otis Company ltd, Xizi Group, Baida Group, Shuanglin Biotechnology Company, Zhejiang United Investment Group Co. ltd. (ZUIG) acting the roles as senior auditor, CFO, Executive Director, Managing Director, etc. She is familiar with China, Hong Kong and International Accounting Standards, specializing in the area of corporate finance, taxation, internal control and operational management with over 20 years’ experience in financial management, investment, financing and capital operation of listed companies.
LLM International Business Law from Erasmus University Rotterdam and LLB from Southwest University of Political Science and Law. Before joining Tigermed, Mr. Liu worked for Huawei, Dahua Technology, Alibaba and other large listed companies. He has been conducting legal compliance work and living overseas for nearly 10 years, managing various complex litigations, tax cases and other disputes with a scale of hundreds of millions of dollars. With nearly 20 years of overseas and international legal and compliance management experience and team management experience, he has in-depth practical exploration and accumulation in building global compliance platforms, forming and operating compliance committees, building compliance systems for export control, data security, tax, employment, ESG, etc.